IntegerBio, Inc.
IntegerBio is at the forefront of Immunovirology, committed to combating serious viral diseases by pioneering the intersection of immunology and virology. The company focuses on developing broad multi-viral therapeutics using cutting-edge biology and data-focused approaches. Their mission is to harness the power of science to design therapeutics with durable responses across multiple viruses, aiming for a future without the fear of viral disease.
Industries
N/A
Nr. of Employees
small (1-50)
IntegerBio, Inc.
Products
IB-001 (preclinical interferon-pathway therapeutic candidate)
A preclinical synthetic protein therapeutic candidate engineered to engage interferon receptors and demonstrate antiviral and anti-inflammatory activity in cell-based and in vivo models.
IB-001 (preclinical interferon-pathway therapeutic candidate)
A preclinical synthetic protein therapeutic candidate engineered to engage interferon receptors and demonstrate antiviral and anti-inflammatory activity in cell-based and in vivo models.
Expertise Areas
- Immunovirology
- Protein engineering for biologics
- Innate immune pathway modulation
- Antiviral drug discovery
Key Technologies
- Type I interferon pathway modulation
- Receptor-targeted cytokine agonists
- Synthetic protein therapeutics
- Cell-based antiviral assays (A549, primary hepatocytes, PBMCs)